Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
1. Ozempic
2. Rybelsus
1. Nn9535
2. Ozempic
3. Rybelsus
4. 910463-68-2
5. Nn 9535
6. Nnc 0113-0217
7. Nn-9535
8. Unii-53axn4nnhx
9. Semaglutide [usan:inn]
10. Wegovy
11. 53axn4nnhx
12. Rybelsus (oral Semaglutide)
13. Gtpl9724
14. Ozempic (injectable Semaglutide)
15. Chebi:167574
16. Ex-a2424
17. Ac-32580
18. Nnc-0113-0217
19. Rybelsus;ozempic;nn9535;og217sc;nnc 0113-0217
Molecular Weight | 4114 g/mol |
---|---|
Molecular Formula | C187H291N45O59 |
XLogP3 | -5.8 |
Hydrogen Bond Donor Count | 57 |
Hydrogen Bond Acceptor Count | 63 |
Rotatable Bond Count | 151 |
Exact Mass | 4112.1187318 g/mol |
Monoisotopic Mass | 4111.1153770 g/mol |
Topological Polar Surface Area | 1650 Ų |
Heavy Atom Count | 291 |
Formal Charge | 0 |
Complexity | 9590 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 30 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;
- in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.
Treatment of obesity
Treatment of type II diabetes mellitus
Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in combination with other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.
Treatment of type II diabetes mellitus
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
- 30 kg/m (obesity), or
- 27 kg/m to < 30 kg/m (overweight) in the presence of at least one weight-related comorbidity e. g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
A10BJ06
A10BJ06
A10BJ06
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BJ - Glucagon-like peptide-1 (glp-1) analogues
A10BJ06 - Semaglutide
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-04-30
Pay. Date : 2023-03-02
DMF Number : 37594
Submission : 2023-03-16
Status : Active
Type : II
NDC Package Code : 55463-0040
Start Marketing Date : 2024-04-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
NDC Package Code : 61281-8600
Start Marketing Date : 2024-09-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6282
Start Marketing Date : 2024-08-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Semaglutide is a GLP-1 receptor agonist, which is being investigated in Phase 3 for the treatment of weight loss type 2 diabetes and chronic kidney disease.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Semaglutide-Generic
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dr Reddy’s Labs Gets Nod to Study Popular Weight Loss Medication
Details : Semaglutide is a GLP-1 receptor agonist, which is being investigated in Phase 3 for the treatment of weight loss type 2 diabetes and chronic kidney disease.
Brand Name : Semaglutide-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 19, 2023
Details:
subcutaneous semaglutide is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Semaglutide-Generic
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dr Reddy's Gears up for Weight Loss Drug Study
Details : subcutaneous semaglutide is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.
Brand Name : Semaglutide-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 18, 2023
Details:
NG101 is an oral, peripherally restricted dopamine D2 receptor antagonist, being investigated for nausea and vomiting side effects caused by GLP-1 agonist medication.
Lead Product(s): Metopimazine Mesylate,Semaglutide
Therapeutic Area: Neurology Brand Name: NG101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2024
Lead Product(s) : Metopimazine Mesylate,Semaglutide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Neurogastrx Shows Positive Data for NG101 in GLP-1 Related Nausea
Details : NG101 is an oral, peripherally restricted dopamine D2 receptor antagonist, being investigated for nausea and vomiting side effects caused by GLP-1 agonist medication.
Brand Name : NG101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2024
Details:
Semaglutide is a peptide GLP-1 agonist, peptide drug candidate, which is being evaluated for the treatment of type 2 diabetes & obesity.
Lead Product(s): Semaglutide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ProLynx Unveils Monthly Dosing Preclinical Results for Long-Acting Semaglutide
Details : Semaglutide is a peptide GLP-1 agonist, peptide drug candidate, which is being evaluated for the treatment of type 2 diabetes & obesity.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 21, 2024
Details:
Wegovy (semaglutide) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Wegovy
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novo Nordisk launches weight-loss drug Wegovy in Australia
Details : Wegovy (semaglutide) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.
Brand Name : Wegovy
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 02, 2024
Details:
In this collaboration, the two parties aim to enhance the clinical evidence supporting the pharmacokinetic profile of semaglutide when delivered by StackDose technology in treating obesity.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Health2Sync
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 25, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Health2Sync
Deal Size : Undisclosed
Deal Type : Collaboration
Merdury Signs MOU with Health2Sync for StackDose Trial in GLP-1 Medication
Details : In this collaboration, the two parties aim to enhance the clinical evidence supporting the pharmacokinetic profile of semaglutide when delivered by StackDose technology in treating obesity.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 25, 2024
Details:
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to reduce the risk of major adverse cardiovascular events in adults.
Lead Product(s): Semaglutide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Wegovy
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Authority Adopts Update to Wegovy® Label for Cardiovascular Risk Reduction
Details : Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to reduce the risk of major adverse cardiovascular events in adults.
Brand Name : Wegovy
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 25, 2024
Details:
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to reduce the risk of major adverse cardiovascular events in adults.
Lead Product(s): Semaglutide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Wegovy
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novo Nordisk's Wegovy Gets UK Approval for Use to Lower Heart Risks
Details : Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to reduce the risk of major adverse cardiovascular events in adults.
Brand Name : Wegovy
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 23, 2024
Details:
NovoCare (semaglutide) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: NovoCare
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy
Details : NovoCare (semaglutide) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.
Brand Name : NovoCare
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 26, 2024
Details:
VTX3232 is an oral CNS-penetrant NLRP3 inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of patients with obesity.
Lead Product(s): VTX3232,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: VTX3232
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Lead Product(s) : VTX3232,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ventyx Biosciences Reveals Positive Data for NLRP3 Inhibitor VTX3232 in Obesity Treatment
Details : VTX3232 is an oral CNS-penetrant NLRP3 inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of patients with obesity.
Brand Name : VTX3232
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2024
CAS Number : 2061897-68-3
End Use API : Semaglutide
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
2-(2-(2-AMINOETHOXY)ETHOXY)ACETIC ACID HYDROCHLORI...
CAS Number : 134979-01-4
End Use API : Semaglutide
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
17-amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan...
CAS Number : 1143516-05-5
End Use API : Semaglutide
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
2,2-Dimethyl-4,13-dioxo-3,8,11,17,20-pentaoxa-5,14...
CAS Number : 1069067-08-8
End Use API : Semaglutide
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
18-(tert-butoxy)-18-oxcoctadecanoic acid
CAS Number : 843666-40-0
End Use API : Semaglutide
About The Company : Saptagir Laboratories Private incorporated in 2016, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and Intermediates for a wide rang...
CAS Number : 1069067-08-8
End Use API : Semaglutide
About The Company : Saptagir Laboratories Private incorporated in 2016, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and Intermediates for a wide rang...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?